IMRT-SIB But-Hadzic | 3D CRT Focas | IMRT-SIB But-Hadzic | IMRT-SIB Li | |||
---|---|---|---|---|---|---|
p | p | |||||
12 (26%) | 40 (10%) | 12 (26 %) | 19 (33 %) | 0.302 | ||
29 (63%) | 254 (66%) | 0.404 | 29 (63 %) | 20 (35 %) | ||
5 (11%) | 91 (24%) | 5 (11 %) | 19 (32 %) |
Treatment | Pelvis TD/d/BED (Gy) | Tumour T≤3 TD/d/BED (Gy) | Tumour T4 TD/d/BED (Gy) |
---|---|---|---|
3D CRT | 45 / 1.8 / | 50.4 / 1.8 / | 54 / 1.8 / |
IMRT-SIB | 41.8 / 1.9 / | 46.2 / 2.1 / | 48.4 / 2.2 / |
Prognostic factor | OS | DFS |
---|---|---|
Age | ns | ns |
Gender | ns | ns |
WHO PS | ns | ns |
Tumour grade | ns | ns |
cTumour stage according the AJCC, 7th edition | ns | ns |
cNodal stage according the AJCC, 7th edition | ns | ns |
TRG | ns | ns |
TRG prognostic group | ns | ns |
pTumour staged | ns | ns |
pNodal staged | p = 0.005 | p = 0.039 |
pCR pathologic complete response | ||
Adjuvant chemotherapy chemotherapy | ns | ns |
5-6 vs. ≤4 cycles calculated for 36 patients with indication for adjuvant chemotherapy; ns = not specific (p > 0.05). | p = 0.009 | p = 0.012 |